RADIATION ONCOLOGY CENTER BUSINESS PLAN

I. Executive Summary

Company Description

Houston Precision Radiation Center draws its name from the city we serve and our focus on millimeter-level targeting. We operate in the healthcare sector, specifically radiation oncology, and will open in Houston in 2026 to deliver advanced outpatient radiation therapy. Core services include image-guided Linear Accelerator treatments, CT simulation, intensity-modulated radiation therapy (IMRT), and stereotactic body radiation therapy (SBRT). We combine those technologies with a patient-centered clinic design and anxiety-reduction protocols to improve adherence and outcomes. One clear promise: precise care, delivered quickly.

Our daily activities include same-day CT simulation-to-treatment workflows, multidisciplinary care planning, on-site dosimetry and physics, and rapid scheduling to avoid hospital delays. We differentiate on throughput and experience: shorter lead times, private treatment suites, and protocols that cut setup time without sacrificing quality. Target patients are adults in the Greater Houston area needing curative or palliative radiotherapy, including referrals from community oncologists and hospital systems. Short-term goals: open Q2 2026, reach 60% capacity by month 12, and document safety and outcome metrics. Long-term goals: expand to two additional satellite clinics by 2029 and sustain a >75% gross margin on technical services. Focused, measurable growth.

Problem

Cancer patients experience fragmented, stressful radiation therapy journeys that cause long scheduling delays, uncoordinated care transitions, and high psychological stress—factors that contribute to delayed radiation therapy and reduced treatment adherence.

Large institutional settings often fail to coordinate diagnostic and therapeutic phases efficiently, creating logistical bottlenecks that worsen clinical timelines and patient experience. There is a critical need for a specialized center that removes these bottlenecks and provides timely, patient-centered radiation care.

Our Houston-based center, launching in 2026, will address this gap by combining state-of-the-art technology (Linear Accelerators, CT Simulators) with a compassionate, efficiency-first operating model to deliver high-precision IMRT and SBRT treatments and faster access to critical care.

Solution

One-liner: A Houston radiation therapy center delivering high-precision treatment in a compassionate, non-clinical setting.

Cancer patients face fragmented, stressful journeys with long waits, impersonal hospital environments, and overburdened radiation departments. Our center combines CT-based simulation + Linear Accelerator technology with streamlined scheduling, patient navigation, and a supportive physical environment to reduce delays, improve targeting of tumor dose, and preserve patient well-being during multi-week treatment courses.

Mission Statement

Our mission is to deliver precise, effective radiation therapy within a compassionate, supportive environment that removes barriers to timely care. We ensure every patient feels seen, heard, and expertly cared for throughout their treatment. We pursue clinical innovation and operational excellence to improve patient outcomes and set a new standard for specialized oncology care.

Key Success Factors

Success depends on clinical trust, operational efficiency, patient experience, and disciplined finances.

• Trusted referral network: oncologists and surgeons who refer based on clinical excellence.
• Specialized clinical staff: IMRT and SBRT specialists delivering superior outcomes.
• Proprietary scheduling software: maximizes equipment use and patient throughput.
• Supportive non-clinical environment: high patient satisfaction driving word-of-mouth.
• Strong financial management: sustained profitability and reinvestment in technology.

Financial Summary

The financial plan shows a strong launch in 2026 with rapid scale and high margins.

Capital required: $6,795,000 total capex. Operating notes: minimum cash -$942,000 (Jun-26), breakeven Jan-26, payback 9 months; project IRR 23% and ROE 215.39%.

Overall, the center is cash-flow positive immediately and delivers a high-return project profile for investors.

Funding Requirements

We require capital to acquire clinical equipment, complete facility buildout, implement core systems, and fund initial operations to reach mid-2026 operational readiness.

Financial snapshot: Year 1 revenue $18,052,000, EBITDA $13,451,000, breakeven in January 2026, full payback within 9 months, 23% IRR, and ROE of 215.39% with projected revenue of $89,292,000 by 2030.